BEAM250117P38000
- 0.00
- 0.000.00%
Beam Therapeutics Newsroom
2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy
Bernstein Upgrades Beam Therapeutics(BEAM.US) to Buy Rating, Raises Target Price to $37
Beam Upgraded by Bernstein Ahead of AATD Data
Beam Therapeutics Price Target Raised to $37 From $35 at Bernstein
Express News | Beam Therapeutics Inc : Bernstein Raises to Outperform From Market Perform; Raises Target Price to $37 From $35
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?
Cathie Wood's ARK Investment Buys 116K Shares of Beam Therapeutics Today
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $42 to $80
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings
Promising Early Data and Innovative Approaches Lead to Buy Rating for Beam Therapeutics
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Monday Ahead of Crucial Inflation Data
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $48